Association of pre-transplant statin use with delayed graft function in kidney transplant recipients

BMC Nephrology

Research Article

Janske Reiling¹  Daryl R Wall²  David W Johnson²  Peter S Kruger³  Peter Pillans⁴ 

[1] Queensland Renal Transplant Service, Princess Alexandra Hospital, Brisbane, Australia;Maastricht University, Maastricht, The Netherlands;Queensland Renal Transplant Service, Princess Alexandra Hospital, Brisbane, Australia;University of Queensland, Brisbane, Australia;University of Queensland, Brisbane, Australia;Intensive Care Unit, Princess Alexandra Hospital, Brisbane, Australia;University of Queensland, Brisbane, Australia;Pharmacology Department, Princess Alexandra Hospital, Brisbane, Australia;

关键词: Atorvastatin;    Renal Transplant Recipient;    Delay Graft Function;    Statin User;    Donation After Cardiac Death;   

DOI  :  10.1186/1471-2369-13-111

 received in 2011-11-28, accepted in 2012-09-14,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundAdministration of HMG-CoA reductase inhibitors (statins), prior to ischemia or prior to reperfusion has been shown to decrease ischemia-reperfusion renal injury in animal studies. It is unknown whether this protective effect is applicable to renal transplantation in humans. The aim of this study was to determine the relationship between prior statin use in renal transplant recipients and the subsequent risk of delayed graft function.MethodsAll patients who underwent deceased or living donor renal transplantation at the Princess Alexandra Hospital between 1 July 2008 and 1 August 2010 were included in this retrospective, observational cohort study. Graft function was classified as immediate graft function (IGF), dialysis-requiring (D-DGF) and non-dialysis-requiring (ND-DGF) delayed graft function. The independent predictors of graft function were evaluated by multivariable logistic regression, adjusting for donor characteristics, recipient characteristics, HLA mismatch and ischaemic times.ResultsOverall, of the 266 renal transplant recipients, 21% exhibited D-DGF, 39% had ND-DGF and 40% had IGF. Statin use prior to renal transplantation was not significantly associated with the risk of D-DGF (adjusted odds ratio [OR] 1.05, 95% CI 0.96 – 1.15, P = 0.28). This finding was not altered when D-DGF and ND-DGF were pooled together (OR 0.98; 95% CI 0.89-1.06, p = 0.56).ConclusionsThe present study did not show a significant, independent association between prior statin use in kidney transplant recipients and the occurrence of delayed graft function.

【 授权许可】

Unknown   
© Reiling et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.